ESMO - Eur. Oncology· @myESMO · X·· 1 day agoScore70
Body · original
#ESMO26: Neoadjuvant enfortumab vedotin significantly improved event-free and overall survival when added to peri-operative durvalumab for muscle-invasive #BladderCancer (#MIBC) in the phase III VOLGA #ClinicalTrial
🔗 https://ow.ly/8zVg50ZZl8e
#InsightsbyESMO #ADC
137 views · 1 like · 0 reposts · 0 replies
Conference abstracts
LBA2matched by Presidential Symposium I
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.orgSource: ESMO - Eur. Oncology · x.com